11 Results

People

  1. Ciardiello
    Ciardiello
  2. Hassoun
    Hassoun
  3. Hultcrantz
    Hultcrantz
  4. Korde
    Korde
  5. Lesokhin
    Lesokhin
  6. Mailankody
    Mailankody
  7. Landgren
    Landgren
  8. Shah
    Shah
  9. Thoren
    Thoren
  10. Chung
    Chung

Groups

  1. Center for Hematologic Malignancies (11)
  2. Department of Medicine (11)
  3. Hematologic Malignancies Research (11)
  4. Hematologic Malignancies, Division of (11)
  5. Myeloma (11)
  6. Sloan Kettering Institute Postdocs (11)
  7. Survivorship Research (11)
  8. CTCR Scholars (9)
  9. Biostatistics Service (7)
  10. Bone Marrow Transplant (7)
  1. "Hematologic Malignancies Research"
  2. "Hani Hassoun"
  3. "Center for Hematologic Malignancies"
  4. "Amanda Ciardiello"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (5)
Groups
  1. Center for Hematologic Malignancies (11)
  2. Department of Medicine (11)
  3. Hematologic Malignancies Research (11)
  4. Hematologic Malignancies, Division of (11)
  5. Myeloma (11)
  6. Sloan Kettering Institute Postdocs (11)

More Groups

People
  1. Alexander Lesokhin (11)
  2. Amanda Ciardiello (11)
  3. Hani Hassoun (11)
  4. Malin Hultcrantz (11)
  5. Neha Korde (11)
  6. Sham Mailankody (11)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (2)
  4. 2020 (3)
  5. 2019 (3)
Publications
  1. Blood (4)
  2. Journal of Clinical Oncology (2)
  3. Blood Cancer Journal (1)
  4. British Journal of Haematology (1)
  5. Clinica Chimica Acta (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (4)
  2. American Society of Clinical Oncology (2)
  3. American Association for Cancer Research (1)
  4. American Medical Association (1)
  5. Elsevier Science BV (1)
  6. John Wiley & Sons (1)

More Publishers

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience
    Meeting Abstract

    Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Journal Article

    Eveillard, M.; Korde, N.; Ciardiello, A.; Diamond, B.; Lesokhin, A.; Mailankody, S.; Smith, E.; Hassoun, H.; Hultcrantz, M.; Shah, U.; more...
    Clinica Chimica Acta (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma
    Journal Article

    Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Lu, S.; Shah, U.; Hassoun, H.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save